Influence of Voriconazole (VRC) on Survival Outcome of Trichosporonemia: Result Epidemiological Study in Japan

Ref ID: 18754

Author:

I. Tokimatsu, MD (Doctor of Medicine) – Assistant Professor, H. Kushima, MD – Student of the postgraduate school, S. Toba, MD – Student of the postgraduate school, J. Kadota, MD – Professor, Japan Trichosporonosis Study Group;

Author address:

Oita Univ. Faculty of Med., Yufu, Japan.

Full conference title:

52nd Annual ICAAC

Date: 9 September 2014

Abstract:

Background: Trichosporonemia, blood stream infection by Trichosporon species, is frequently fatal mycosis. Standard therapy has not been yet. Because trichosporonemia is frequently developed in hematological malignant diseases, many factors influence the outcome of this infection. The present study was carried out to clarify the factors of patients with a more favorable outcome in trichosporonemia. Methods: 63 patients with trichosporonemia recorded to our study group were studied retrospectively. We analyzed 23 factors associated with 30-days survival outcome in patients by classification and regression trees (CART) statistics: gender, age, peripheral white blood cell counts at the diagnosis of trichosporonemia, information on antifungal drugs used prior to diagnosis of trichosporonemia, stem cell transplantation, immunosuppressive therapy, cytotoxic chemotherapy, adrenal corticosteroid therapy, central venous catheterization, and information antifungal used after onset of trichosporonemia. Results: The mortality rate within 30 days was 61.9%. In CART analysis, the strongest impact factor for 30-day survival was an administration of VRC after onset of trichosporonemia: 13/20 patients (65%) were survival in VRC group vs. 11/43 patients (26%) were survival in without VRC group. In the next branch by CART analysis, the breakthrough trichosporonemia was influence factor to 43 patients of without VRC group for survival outcome: 5/8 patients (63%) were survival in without breakthrough group vs. only 6/35 patients (17%) were survival in breakthrough group. Conclusions: This present study confirmed that VRC was a useful antifungal agent for trichosporonemia. It was note worthy that the stronger impact factor to 30-day survival outcome of trichosporonemia was “œadministration of VRC” than “œbreakthrough trichosporonemia” and “œneutropenia”. We believe that the use of VRC encourages physicians in the treatment of trichosporonemia.

Abstract Number: M-324

Conference Year: 2012

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster